Incubator Companies
Lab On Chip Device For Spore Detection
This project focuses on the development of a lab on chip rapid detection platform capable of being adapted to many markets from the defence sector where detection of pathogenic bacteria and other biological threats to human life are encountered or in the protection of key resources such as public water supplies. In adopting a platform development approach the company aims to facilitate novel monitoring applications as well as wide area network monitoring by lowering capital cost requirements.
Holographic sensing is being developed as novel detection mechanism in specific biological sensing applications and will be developed for this platform. This will be incorporated into a handheld “lab on a chip” device based on optical holographic sensing designed for the rapid detection of the germination of bacterial spores.
Working closely in conjunction with the Institute of Biotechnology at the University of Cambridge and the MMP group at SIMTech in Singapore, real time pathogen detection by means of germination sensing becomes possible by using holographic techniques.
The initial chip platform is being designed to lend itself to the development of a second generation family of products and the expansion of the chip platform to units capable of multiple organism detection.
Sparq Wireless Solutions
Sparq Wireless Solutions is developing and commercialising a portfolio of intellectual property in wireless communications and wireless sensing, particularly in nanotechnology and novel small scale systems. Sparq is currently working with two promising technologies involving the utilization of electroacoustic behaviour with piezoelectric structure.
Molbot
MolBot is a Singapore-based startup, that has been established to develop small lab-in-a-box workstations to meet a pressing need for automation in biomedical lab-work.
MolBot was founded by molecular biologists Dr Patrick Gilligan and Dr Daniel Kirilly, with a combined 21 years of research experience (16 of those in Singapore). Molbot chose to locate itself in Singapore due to the founder’s familiarity with the local research environment and Singapore’s world class engineering prototyping, manufacturing facilities and world class biomedical research institutes.
Biomedical research is an exciting $200 Billion a year endeavour. Despite being highly technical, biomedical research is often manually laborious and repetitive.
MolBots biochemistry will be performed on disposable self-contained plastic chips, with versatile modules for DNA purification, amplification and analysis. The integrated chip design will achieve walk-away automation of complex tasks.
Nova Parking Ltd
Are developing a wireless network system to facilitate On-street and Off-street managed parking using their micro parking meters™ which detect where vehicles are parked and where free spaces are available. Nova Parking's networked system enables drivers to wirelessly connect to no-touch automatic payments.
Nova Parking's information network and servers, manage data from the micro parking meters in realtime. This gives users and operators the ability to access parking maps showing occupancy on their mobile device. The tailored information is routed through to drivers and parking operators.
Nova Parking’s platform provides drivers and wardens with real time parking-status information for every vehicle in their vicinity. www.novaparking.com
JN Medsys
JN Medsys Pte Ltd is a new Singapore start-up company dedicated to the research and development of affordable and leading-edge instruments for digital PCR (dPCR), the next generation of PCR that can lead to more sensitive and improved diagnostics. It is founded by Dr Johnson Ng, a Singaporean with a PhD in Bioengineering from the National University of Singapore. Johnson has 8 years of experience in developing platforms for PCR and nucleic acid-based molecular diagnostics, including the past three years as pioneer staff in Biochip Devises, a Singapore-based biomedical device start-up.
In founding JN Medsys, Johnson hopes to identify potential growth areas with unmet needs in nucleic acid-based diagnostics, and then gather a team of like-minded individuals with diverse expertise to develop affordable and innovative products to meet those needs, starting with the emerging digital PCR instrument market. It is hoped that this team will drive JN Medsys to be global company. This would put Singapore onto the world map of medtech innovation, compete for a share of the worldwide market dominated by US and European companies, and thereby contribute to the local economy and our drive for excellence in research and innovation.
